January 30, 2012 – Endo Pharmaceuticals Announces Potential for Short Supply of Pain Medicines Endo Pharmaceuticals back on January 9th, as a result of a temporary shut-down of Novartis Consumer Health Inc.’s Lincoln, Neb., manufacturing facility, there will be a short-term supply constraint of OPANA® ER.  The company also announced certain other Endo analgesic products manufactured [...]

November 22, 2011 – Watson Pharmaceuticals, a company based in Corona, CA, announced on November 11th that the U.S. Food and Drug Administration (FDA) has approved their Abbreviated New Drug Application (ANDA) for a generic version of Kadian.  This long-acting morphine sulfate preparation is indicated for the management of moderate to severe pain requiring around-the-clock [...]

September 15, 2011 – Generic versions of the brand name drug, Keppra XR, are being launched this month by both Watson Laboratories and Lupin Ltd.  And both companies have begun shipping their products. Both companies are producing AB rated versions of levetiracetam in 500mg and 750mg strengths.  Levetiracetam is indicate for the adjunctive therapy to [...]

September 15, 2011 – Johnson & Johnson obtained approval from the US Food & Drug Administration (FDA) for the long-acting version of tapentadol, Nucynta ER.  The medication is designed to be taken twice daily for the control of moderate to severe chronic pain in adults when a continuous, 24-hour opioid analgesic is needed for an [...]

September 15, 2011 – The US FDA has issued a warning stating that citalopram hydrobromide, an antidepressant sold generically and under the brand name Celexa, should not be administered at doses over 40 mg per day, because it can trigger abnormal electrical activity in the heart, leading to potentially fatal heart rhythm problems (including Torsade [...]